Last reviewed · How we verify
Acetaminophen, Gabapentin
This combination reduces pain through acetaminophen's central analgesic and antipyretic effects plus gabapentin's modulation of calcium channels to reduce neuropathic pain signaling.
This combination reduces pain through acetaminophen's central analgesic and antipyretic effects plus gabapentin's modulation of calcium channels to reduce neuropathic pain signaling. Used for Neuropathic pain conditions, Acute and chronic pain management.
At a glance
| Generic name | Acetaminophen, Gabapentin |
|---|---|
| Also known as | Opioid-free preoperative medications, Opioid-containing preoperative medications |
| Sponsor | University of Saskatchewan |
| Drug class | Analgesic combination (non-opioid analgesic + anticonvulsant) |
| Target | Prostaglandin synthesis (acetaminophen); voltage-gated calcium channel alpha-2-delta subunit (gabapentin) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Neurology |
| Phase | Phase 3 |
Mechanism of action
Acetaminophen works primarily through central inhibition of prostaglandin synthesis and modulation of descending pain pathways. Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels, reducing the release of excitatory neurotransmitters involved in pain transmission. Together, they provide complementary analgesic mechanisms targeting both nociceptive and neuropathic pain.
Approved indications
- Neuropathic pain conditions
- Acute and chronic pain management
Common side effects
- Dizziness
- Somnolence
- Headache
- Nausea
- Hepatotoxicity (acetaminophen)
- Peripheral edema
Key clinical trials
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
- Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients (PHASE4)
- Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia (PHASE3)
- CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs (NA)
- Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (PHASE2)
- Effectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA) (NA)
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetaminophen, Gabapentin CI brief — competitive landscape report
- Acetaminophen, Gabapentin updates RSS · CI watch RSS
- University of Saskatchewan portfolio CI